Markets

ResMed (RMD) Closes MatrixCare Buyout, Boosts SaaS Line

Staying ahead of expectations, ResMed Inc.RMD recently completed its $750 million acquisition of the privately held MatrixCare. This is a long-term post-acute care software, offering a complete solution for growing organizations that need to successfully manage risk in care delivery across the long-term post-acute care (LTPAC) spectrum.

Per the financial terms of the transaction, this acquisition is expected to be immediately accretive to ResMed's adjusted earnings per share and its adjusted gross margin.

MatrixCare's electronic health record (EHR) solution supports a wide range of long-term care settings that helps increase patient management efficiencies, delivering a superior clinical care. Its offerings include point of care, lead and referral management, claims processing plus payroll and nutrition management among others.

According to ResMed, this buyout will enhance its ability to improve patient transitions of care and provider efficiencies. Post the integration of MatrixCare, the company's portfolio will comprise Brightree, HEALTHCARE first and MatrixCare. ResMed believes that this strategic move will streamline its transitions of care, creating better outcomes for patients, caregivers and out-of-hospital healthcare providers.

Post closure, MatrixCare will now continue to operate as a standalone business within ResMed's SaaS portfolio with targeted commercial, technical and operating links to ResMed and Brightree. There will be no instant changes to the acquired entity's management, locations or business processes.

ResMed is currently seeking a treatment option for chronic lung disease patients, which will allow them to stay out of hospital by lending a high-quality life within the comfort zone of their own homes. By its own admission, such enhanced connected health solutions for out-of-hospital medical software market are aiding ResMed to continue with the favorable momentum.

Share Price Performance

In the past month, shares of ResMed have outperformed its industry . The stock has dipped 4.2% compared with the 6.7% decline of the industry.

Zacks Rank & Key Picks

ResMed has a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Stryker Corporation SYK , Masimo Corporation MASI and Veeva Systems VEEV .

Stryker has estimated long-term earnings growth rate of 10% and a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Masimo's long-term earnings growth rate is projected at 14.6%. The stock carries a Zacks Rank of 2.

Veeva Systems' long-term earnings growth rate is projected at 19.3%. The stock is a Zacks #2 Ranked player.

Wall Street's Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Veeva Systems Inc. (VEEV): Free Stock Analysis Report

Masimo Corporation (MASI): Free Stock Analysis Report

ResMed Inc. (RMD): Free Stock Analysis Report

Stryker Corporation (SYK): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MASI VEEV SYK RMD

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More